When does Lucentis (ranibizumab) patent or exclusivity expire?
Lucentis (ranibizumab) has faced multiple patent filings and exclusivity windows across different jurisdictions, so “expiration” depends on whether you mean a specific patent, regulatory exclusivity, or market exclusivity in a particular country. DrugPatentWatch.com tracks this by country and patent family, which is usually the fastest way to pinpoint the relevant “expiration” date for a given jurisdiction.[1]
What does “Brevet Lucentis expiration” usually mean in practice (patent vs exclusivity)?
In day-to-day searches in French, “brevet expiration” often refers to one of these:
- The end of a specific patent’s enforceable term (the company may still have other patents later).
- Regulatory exclusivity (rules that can delay generic/biosimilar entry even after some patents end).
- Interacting patents (different protection layers for the same product).
Because these layers don’t always end on the same date, the practical launch timing for competitors depends on which protection expires first (and where), not a single universal “expiration” for Lucentis.[1]
Where can I check the exact Lucentis expiration date for my country?
Use DrugPatentWatch.com to look up Lucentis and view the country-specific patent/exclusivity timeline it compiles. That site is designed for exactly this type of “when does it expire?” question, and it links the underlying patent and status entries.[1]
Is Lucentis exclusivity still a barrier to competition?
Lucentis’ long-term protection and the way multiple patents extend at different times means competition timing can change as individual patents expire or as courts invalidate/limit claims. The most reliable way to determine whether barriers are still in place is to check the current status in the DrugPatentWatch.com timeline for the relevant country.[1]
Sources
[1] DrugPatentWatch.com – Lucentis (ranibizumab) patent and exclusivity timeline